Recent DRAFT NICE guidance did not recommend liposomal cytarabine and daunorubicin, within its anticipated marketing authorisation, for treating newly diagnosed, therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults, as the most likely cost-effectiveness estimates were above the range that NICE normally considers acceptable.